| Literature DB >> 27382190 |
Andrea Schnúr1, Péter Hegyi2, Simon Rousseau3, Gergely L Lukacs4, Guido Veit1.
Abstract
The pivotal role of epithelial cells is to secrete and absorb ions and water in order to allow the formation of a luminal fluid compartment that is fundamental for the epithelial function as a barrier against environmental factors. Importantly, epithelial cells also take part in the innate immune system. As a first line of defense they detect pathogens and react by secreting and responding to chemokines and cytokines, thus aggravating immune responses or resolving inflammatory states. Loss of epithelial anion transport is well documented in a variety of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, pancreatitis, and cholestatic liver disease. Here we review the effect of aberrant anion secretion with focus on the release of inflammatory mediators by epithelial cells and discuss putative mechanisms linking these transport defects to the augmented epithelial release of chemokines and cytokines. These mechanisms may contribute to the excessive and persistent inflammation in many respiratory and gastrointestinal diseases.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27382190 PMCID: PMC4921137 DOI: 10.1155/2016/7596531
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Schematic depiction of the anion transport pathways in secretory epithelia. Apical chloride (Cl−) and bicarbonate (HCO3 −) efflux is mediated by CFTR and TMEM16A and probably members of the SLC26A family. Basolateral chloride and bicarbonate entry is conducted by cation cotransporters NKCC1 and NBC1, respectively. Alternatively chloride entry at the basolateral membrane is conducted by chloride-bicarbonate exchange via AE2. Carbonic anhydrase (CA) catalyzes the de novo formation of bicarbonate. Examples for the cytokine-mediated regulation of channel function or expression are indicated.
Anion transport activity changes and proinflammatory chemokine and cytokine secretion in different diseases.
| Disease | Transporter/channel function | Augmented chemokines/cytokines | |
|---|---|---|---|
| Airway system | CF | CFTR ↓ | CXCL8, CXCL1, CXCL2, CCL3, CCL18, IL-1 |
| COPD | CFTR ↓ | CXCL8, CXCL1, CCL2, CCL8, CCL18, IL-6 | |
| Asthma | CFTR | CXCL8, IL-1 | |
|
| |||
| Gastrointestinal system | Pancreatitis | CFTR | CXCL8, IL-1, IL-6, TNF- |
| Cholestatic liver diseases | CFTR | CXCL8, CXCL1, CXCL5, CXCL6, CXCL10, CCL2, CCL3, CCL4, CCL5, | |
CFTR: carriers of CFTR mutations have an increased risk to develop disease.
Clinical trials for CF therapy indirectly targeting the lack of CFTR-mediated anion transport in the lung by ion-replacement or activation of alternative anion channels.
| Therapeutic approach | Compound | Type of administration | Result | References |
|---|---|---|---|---|
| Mucus rehydration | Hypertonic saline | Nebulized | Modest increase in lung function | [ |
|
| ||||
| Antioxidant treatment | GSH | Nebulized | Small or no effect on lung function | [ |
| N-acetylcysteine | Oral | Modest increase in lung function | [ | |
|
| ||||
| TMEM16A function | Denufosol | Inhaled | Small or no effect on lung function | [ |
Figure 2Putative mechanisms linking impaired anion transport to augmented epithelial chemokine signaling in secretory epithelia. (a) Low ASL in CF results in elevated concentrations of CXCL chemokines due to the reduced liquid volume in the luminal compartment. The increased concentration gradient enhances the neutrophil chemotaxis [250]. (b) Low ASL pH may directly activate chemokine expression by activating acid-sensing signaling pathways via proton-sensing GPCRs, ErbB1, and ErbB2 or the soluble protein SPLUNC1. (c) The decreased ROS buffering capacity of the ASL due to the reduced GSH concentration may promote hydrogen peroxide (H2O2) mediated metalloproteinase (MMP) activation. These in turn cleave pro-erbB1 ligands resulting in erbB1 activation, thus initiating signaling pathways that lead to the upregulation of chemokine expression [285].